Zinc potentiates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced dopamine depletion in caudate nucleus of mice brain

Neuroscience Letters

Volumn 335, Issue 1, 2002, Pages 25-28

  Hussain, Saber ^a,c   Ali, Syed F ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c AIR FORCE RESEARCH LABORATORY   (United States)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopamine; Mice; Zinc

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; ZINC;

ANIMAL TISSUE; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; DEPLETION; DOPAMINE BLOOD LEVEL; DOPAMINERGIC SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CAUDATE NUCLEUS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DRUG SYNERGISM; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; SUBSTANTIA NIGRA; ZINC COMPOUNDS;

EID: 0037137504     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(02)01158-8     Document Type: Article

References (27)

1. Adams J.D. Jr, Odunze I.N. Biochemical mechanisms of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine toxicity: could oxidative stress be involved in the brain? Biochem. Pharmacol. 41:1991;1099-1105.
2. Agid Y., Javoy-Agid F., Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. Marsden C.D., Fahn S. Movement Disorders 2. 1987;166-230 Butterworths, London.
3. Ali S.F., David S.N., Newport G.D., Cadet J.L., Slikker W. Jr. MPTP-induced oxidative stress and neurotox-icity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse. 18:1994;27-34.
4. Bush A.I., Pettingell W.H., Multhaup G., dParadis M., Vonsattel J.P., Gusella J.F., Beyreuther K., Masters C.L., Tanzi R.E. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science. 265:1994;464-1467.
5. +, a metabolite of MPTP, brain synaptosomes, Biochem. Biophys. Res. Commun. 128:1985;1228-1232.
6. Chiba K., Trevor A., Castagnoli N. Jr. Metabolism of the neurotoxic tertiary amine MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:1984;574-578.
7. Chung S.H., Johnson M.S. Divalent transition metal ions (Cu and Zn) in the brains of epileptogenic and normal mice. Brain Res. 280:1983;323-334.
8. +-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport. Brain Res. 715:1996;1-8.
9. Ebadi M., Iversen P.L., Hao R., Cerutis D.R., Rojas P., Happe H.K., Murrin L.C., Pfeiffer R.F. Expression and regulation of brain metallothionein. Neurochem. Int. 27:1995;1-22.
10. Ebadi M. Metallothioneins and zinc-binding proteins in brain. Methods Enzymol. 205:1991;363-387.
11. Fahn S. Parkinsonism. Wyngaarden J.B., Smith L.H. Jr. Cecil's Textbook of Medicine. 1988;2143-2147 Saunders, Philadelphia, PA.
12. Frederickson C.J. Neurobiology of zinc and zinc-containing neurons. Int. Rev. Neurobiol. 31:1989;145-238.
13. Fukahori M., Itoh M. Effects of dietary zinc status on seizure susceptibility and hippocampal zinc content in the El (epilepsy) mouse. Brain Res. 529:1990;16-22.
14. +-induced toxicity: comparison between MN9D cells and CHO cells. Toxicol. Lett. 104:1999;49-56.
15. Jimenez I., Gotteland M., Zarzuelo A., Uauy R., Speisky H. Loss of the metal binding properties of metallothionein induced by hydrogen peroxide and free radicals. Toxicology. 120:1997;37-46.
16. Kagi J.H., Vasak M., Lerch K., Gilg D.E., Hunziker P., Bernhard W.R., Good M. Structure of mammalian metallothionein. Environ. Health Perspect. 54:1984;93-103.
17. Langston J.W., Ballard P., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
18. McCrodden J.M., Tipton K.F., Sullivan J.P. The neurotoxicity of MPTP and relevance to Parkinson's disease. Pharmacol. Toxicol. 67:1990;8-13.
19. Palmiter R.D., Findley S.D., Whitmore T.E., Durnam D.M. MT-III, a brain-specific member of the metallothionein gene family. Proc. Natl. Acad. Sci. USA. 89:1992;6333-6337.
20. Przedborski S., Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin. Neurosci. Res. 1:2001;407-418.
21. Rojas P., Hidalgo J., Ebadi M., Rios C. Changes of metallothionein I+II proteins in the brain after 1-methyl- 4-phenylpyridinium administration in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry. 24:2000;143-154.
22. Rossetti Z.L., Sotgiu A., Sharp D.E., Hadjiconstantinou M., Neff N.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine (MPTP) and free radicals in vitro. Biochem. Pharmacol. 37:1988;4573-4574.
23. Sandler M., Glover V., Clow A., Jarman J. Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease: a role for superoxide dismutase? [Review]. Adv. Neurol. 60:1993;238-241.
24. Schapira A.H. MPTP and other Parkinson-inducing agents [Review]. Curr. Opin. Neurol. Neurosurg. 5:1992;396-400.
25. Schetz J.A., Chu A., Sibley D.R. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms. J. Pharmacol. Exp. Ther. 289:1999;956-964.
26. Sterman M.B., Shouse M.N., Fairchild M.D., Belsito O. Kindled seizure induction alters and is altered by zinc absorption. Brain Res. 383:1986;382-386.
27. Williams A., Waring R. The MPTP tale: pathway to prevention of Parkinson's disease? [Review]. Br. J. Hosp. Med. 49:1993;716-719.